V940

V940 refers to the personalized mRNA cancer vaccine candidate developed by moderna and Merck & Co. (Keytruda manufacturer), specifically targeting resected melanoma in an adjuvant setting.

Key Developments

• Clinical Trial Results: Positive Phase 3 trial results announced for the vaccine (Intismeran Autogene).
• Therapeutic Context: Evaluated as an adjuvant therapy for patients with resected melanoma.
• Mechanism: Utilizes mRNA technology to stimulate an immune response against tumor-specific antigens.
• Combination Therapy: Investigated in conjunction with Keytruda (pembrolizumab) to enhance anti-tumor efficacy.

References

• Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy
• How Big of a Deal is this Cancer Vaccine? (Hank Green, 2026-08-29)